Below are some of the most frequently asked questions about our company. If you don't find what you're looking for here, please contact us directly.
Therapix trades on NASDAQ under the ticker TRPX.
Only when the company raises funds and is subject to issuance by the company.
Through a licensed stock broker or by using an online trading account.
March 2017 on NASDAQ
By December 31st
Therapix does not currently have a dividend plan.
Through your licensed stock broker
The Bank of New York Mellon
Kost Forer Gabbay & Kasierer a member of Ernst & Young Global
We announce our earnings release every quarter. To receive email updates, please sign up for alerts here.
The 505(b)(2) is an FDA regulatory pathway with abbreviated development costs and potentially expedited time to market.
Therapix is engaged in drug development for THX-110 for the treatment of Tourette syndrome (Phase IIb), Obstructive Sleep Apnea (Phase IIa) and chronic pain (Phase IIa), THX-130 for the treatment of Traumatic Brain Injury and Mild Cognitive Impairment (pre-clinical), THX-150 for the treatment of infectious disease (pre-clinical) and THX-160 for chronic pain (pre-clinical). Please see our clinical pipeline here.
Therapix most recent Investor materials can be found here.
4 Ariel Sharon St.
HaShahar Tower, 16th floor
Givatayim, IL 5320047
Therapix officially delisted from the Tel Aviv Stock Exchange (TASE) on August 9th, 2018.
For news updates, please sign up for alerts here.
The date and location of the Therapix Annual Meeting of Stockholders for 2018 has not yet been announced.